(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
July 27 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday trimmed its 2023 view for declining sales of its flagship arthritis drug Humira despite new competition, as favorable positions on ...
A lawsuit has been filed against pharmaceutical giant AbbVie over the high price tag on its best-selling drug Humira and a practice it allegedly engages in to help pharmacy benefit managers pocket ...
Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings? Lowering drug prices for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback